BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 23588203)

  • 1. Pharmacological inhibition of polycomb repressive complex-2 activity induces apoptosis in human colon cancer stem cells.
    Benoit YD; Witherspoon MS; Laursen KB; Guezguez A; Beauséjour M; Beaulieu JF; Lipkin SM; Gudas LJ
    Exp Cell Res; 2013 Jun; 319(10):1463-70. PubMed ID: 23588203
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of PRC2 histone methyltransferase activity increases TRAIL-mediated apoptosis sensitivity in human colon cancer cells.
    Benoit YD; Laursen KB; Witherspoon MS; Lipkin SM; Gudas LJ
    J Cell Physiol; 2013 Apr; 228(4):764-72. PubMed ID: 23001792
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Superior efficacy of a combined epigenetic therapy against human mantle cell lymphoma cells.
    Fiskus W; Rao R; Balusu R; Ganguly S; Tao J; Sotomayor E; Mudunuru U; Smith JE; Hembruff SL; Atadja P; Marquez VE; Bhalla K
    Clin Cancer Res; 2012 Nov; 18(22):6227-38. PubMed ID: 22932665
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epigenetic therapy with 3-deazaneplanocin A, an inhibitor of the histone methyltransferase EZH2, inhibits growth of non-small cell lung cancer cells.
    Kikuchi J; Takashina T; Kinoshita I; Kikuchi E; Shimizu Y; Sakakibara-Konishi J; Oizumi S; Marquez VE; Nishimura M; Dosaka-Akita H
    Lung Cancer; 2012 Nov; 78(2):138-43. PubMed ID: 22925699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Restoration of IGF2 imprinting by polycomb repressive complex 2 docking factor SUZ12 in colon cancer cells.
    Wang H; Ge S; Qian G; Li W; Cui J; Wang G; Hoffman AR; Hu JF
    Exp Cell Res; 2015 Nov; 338(2):214-21. PubMed ID: 26407907
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antitumor effects of pharmacological EZH2 inhibition on malignant peripheral nerve sheath tumor through the miR-30a and KPNB1 pathway.
    Zhang P; Yang X; Ma X; Ingram DR; Lazar AJ; Torres KE; Pollock RE
    Mol Cancer; 2015 Mar; 14():55. PubMed ID: 25890085
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chromatin regulator PRC2 is a key regulator of epigenetic plasticity in glioblastoma.
    Natsume A; Ito M; Katsushima K; Ohka F; Hatanaka A; Shinjo K; Sato S; Takahashi S; Ishikawa Y; Takeuchi I; Shimogawa H; Uesugi M; Okano H; Kim SU; Wakabayashi T; Issa JP; Sekido Y; Kondo Y
    Cancer Res; 2013 Jul; 73(14):4559-70. PubMed ID: 23720055
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The histone methyltransferase inhibitor, DZNep, up-regulates TXNIP, increases ROS production, and targets leukemia cells in AML.
    Zhou J; Bi C; Cheong LL; Mahara S; Liu SC; Tay KG; Koh TL; Yu Q; Chng WJ
    Blood; 2011 Sep; 118(10):2830-9. PubMed ID: 21734239
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacologic disruption of Polycomb Repressive Complex 2 inhibits tumorigenicity and tumor progression in prostate cancer.
    Crea F; Hurt EM; Mathews LA; Cabarcas SM; Sun L; Marquez VE; Danesi R; Farrar WL
    Mol Cancer; 2011 Apr; 10():40. PubMed ID: 21501485
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhancer of zeste homolog 2 is overexpressed and contributes to epigenetic inactivation of p21 and phosphatase and tensin homolog in B-cell acute lymphoblastic leukemia.
    Chen J; Li J; Han Q; Sun Z; Wang J; Wang S; Zhao RC
    Exp Biol Med (Maywood); 2012 Sep; 237(9):1110-6. PubMed ID: 22956625
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined inhibition of EZH2 and histone deacetylases as a potential epigenetic therapy for non-small-cell lung cancer cells.
    Takashina T; Kinoshita I; Kikuchi J; Shimizu Y; Sakakibara-Konishi J; Oizumi S; Nishimura M; Dosaka-Akita H
    Cancer Sci; 2016 Jul; 107(7):955-62. PubMed ID: 27116120
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EZH2 Inhibition Blocks Multiple Myeloma Cell Growth through Upregulation of Epithelial Tumor Suppressor Genes.
    Hernando H; Gelato KA; Lesche R; Beckmann G; Koehr S; Otto S; Steigemann P; Stresemann C
    Mol Cancer Ther; 2016 Feb; 15(2):287-98. PubMed ID: 26590165
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual Inhibition of EZH2 and EZH1 Sensitizes PRC2-Dependent Tumors to Proteasome Inhibition.
    Rizq O; Mimura N; Oshima M; Saraya A; Koide S; Kato Y; Aoyama K; Nakajima-Takagi Y; Wang C; Chiba T; Ma A; Jin J; Iseki T; Nakaseko C; Iwama A
    Clin Cancer Res; 2017 Aug; 23(16):4817-4830. PubMed ID: 28490465
    [No Abstract]   [Full Text] [Related]  

  • 14. Dual inhibition of enhancer of zeste homolog 1/2 overactivates WNT signaling to deplete cancer stem cells in multiple myeloma.
    Nakagawa M; Fujita S; Katsumoto T; Yamagata K; Ogawara Y; Hattori A; Kagiyama Y; Honma D; Araki K; Inoue T; Kato A; Inaki K; Wada C; Ono Y; Yamamoto M; Miura O; Nakashima Y; Kitabayashi I
    Cancer Sci; 2019 Jan; 110(1):194-208. PubMed ID: 30343511
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells.
    Tan J; Yang X; Zhuang L; Jiang X; Chen W; Lee PL; Karuturi RK; Tan PB; Liu ET; Yu Q
    Genes Dev; 2007 May; 21(9):1050-63. PubMed ID: 17437993
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells.
    Fiskus W; Wang Y; Sreekumar A; Buckley KM; Shi H; Jillella A; Ustun C; Rao R; Fernandez P; Chen J; Balusu R; Koul S; Atadja P; Marquez VE; Bhalla KN
    Blood; 2009 Sep; 114(13):2733-43. PubMed ID: 19638619
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EZH2 inhibition enhances the efficacy of an EGFR inhibitor in suppressing colon cancer cells.
    Katona BW; Liu Y; Ma A; Jin J; Hua X
    Cancer Biol Ther; 2014; 15(12):1677-87. PubMed ID: 25535899
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bach1 regulates self-renewal and impedes mesendodermal differentiation of human embryonic stem cells.
    Wei X; Guo J; Li Q; Jia Q; Jing Q; Li Y; Zhou B; Chen J; Gao S; Zhang X; Jia M; Niu C; Yang W; Zhi X; Wang X; Yu D; Bai L; Wang L; Na J; Zou Y; Zhang J; Zhang S; Meng D
    Sci Adv; 2019 Mar; 5(3):eaau7887. PubMed ID: 30891497
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PRC2 specifies ectoderm lineages and maintains pluripotency in primed but not naïve ESCs.
    Shan Y; Liang Z; Xing Q; Zhang T; Wang B; Tian S; Huang W; Zhang Y; Yao J; Zhu Y; Huang K; Liu Y; Wang X; Chen Q; Zhang J; Shang B; Li S; Shi X; Liao B; Zhang C; Lai K; Zhong X; Shu X; Wang J; Yao H; Chen J; Pei D; Pan G
    Nat Commun; 2017 Sep; 8(1):672. PubMed ID: 28939884
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role and mechanisms of polycomb repressive complex 2 on the regulation of osteogenic and neurogenic differentiation of stem cells.
    Cao Y; Li L; Fan Z
    Cell Prolif; 2021 May; 54(5):e13032. PubMed ID: 33759287
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.